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ABSTRACT Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), is
a life-threatening pathogen in hospital- and community-acquired infections. The
golden-colored carotenoid pigment of S. aureus, staphyloxanthin, contributes to the
resistance to reactive oxygen species (ROS) and host neutrophil-based killing. Here,
we describe a novel inhibitor (NP16) of S. aureus pigment production that reduces
the survival of S. aureus under oxidative stress conditions. Carotenoid components
analysis, enzyme inhibition, and crtN mutational studies indicated that the molecular
target of NP16 is dehydrosqualene desaturase (CrtN). S. aureus treated with NP16
showed increased susceptibility to human neutrophil killing and to innate immune
clearance in a mouse infection model. Our study validates CrtN as a novel druggable
target in S. aureus and presents a potent and effective lead compound for the de-
velopment of virulence factor-based therapy against S. aureus.
IMPORTANCE S. aureus staphyloxanthin contributes substantially to pathogenesis
by interfering with host immune clearance mechanisms, but it has little impact on
ex vivo survival of the bacterium. Agents blocking staphyloxanthin production may
discourage the establishment and maintenance of bacterial infection without exert-
ing selective pressure for antimicrobial resistance. Our newly discovered CrtN inhibi-
tor, NP16, may offer an effective strategy for combating S. aureus infections.
KEYWORDS MRSA, anti-virulence, bacterial infection, staphyloxanthin
Staphyloxanthin has proven to be an important factor in promoting bacterial invasion(1). Five genes, crtOPQMN, located in an operon are responsible for the biosynthesis of
the pigment. The transcription of the operon is driven by a B-dependent promoter
upstream of crtO and ends with a terminator downstream of crtN (2).
The pigments that endow S. aureus with a golden color (Fig. 1) also make it resistant
to attack from reactive oxygen species (ROS) and neutrophils (3). Pigmented bacteria
have increased resistance to the host’s immune defenses (4).
In a mouse subcutaneous model of infection, animals infected with a wild-type
strain of S. aureus had higher bacterial loads and larger visible lesions than those
infected with nonpigmented bacteria (4). The reduced virulence of bacterial strains with
defective carotenoid synthesis was also shown in a mouse systemic S. aureus infection
model (3). In vitro and in vivo data suggest that blocking pigment synthesis may reduce
pathogenicity.
Dehydrosqualene synthase (CrtM), which catalyzes the ﬁrst step of the biosynthetic
pathway, was shown to be a target for anti-infective therapy, based on virulence factor
neutralization. A drug candidate already tested in humans in the context of cholesterol-
lowering therapy provides a good lead, based on its structural similarity to human
squalene synthase (SQS) (3). Because of common structural features, agents selective
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for S. aureus CrtM and human SQS will have similar side effects. Diphenylamine was
found to be an inhibitor of 4,4-diapophytoene desaturase (CrtN) at a high-micromolar
level (5). Another potential inhibitor of CrtN, naftiﬁne, is an FDA-approved antifungal
compound shown to reduce bacterial loads in mice in different models (6). Following
an established screening method for ﬁnding agents that reduce S. aureus pigmentation
(7), we identiﬁed a compound, which we termed NP16, that blocks pigment production
in S. aureus by targeting the 4,4-diapophytoene desaturase, a novel target proposed for
anti-virulence treatments in S. aureus.
RESULTS
Compound NP16 reduces pigment production. Compound NP16 (structure
shown in Fig. 2C) has potent activity against S. aureus pigment formation in vitro, as
shown in Fig. 2A, with 50% inhibitory concentration (IC50) 300 nM (Fig. 2B). In the
biosynthesis of staphyloxanthin, the product of CrtN, 4,4=-diaponeurosporene, is a yellowish
compound, while products prior to CrtM catalysis in this pathway are colorless (Fig. 1).
Thus, NP16 treatment might target CrtM or CrtN or other regulators that affect the
expression of the crtOPQMN cluster, such as sigB or ispA (8). To test whether regulators
are involved, RNA samples were extracted from NP16-treated and untreated cultures,
and quantitative PCR was conducted to compare crtM and crtN expression levels. No
differences were observed among the tested samples. NP16 did not inhibit the growth
of COL (Fig. 2D) with MIC greater than 500 M (Fig. 2D).
Taken together, these results indicate that NP16 is an inhibitor of CrtM or CrtN.
FIG 1 Biosynthesis pathway of staphyloxanthin. First, in staphyloxanthin biosynthesis, two molecules of
farnesyl diphosphate are condensed head-to-head to form dehydrosqualene (4,4=-diapophytoene); this
reaction is catalyzed by the dehydrosqualene synthase CrtM. Second, dehydrosqualene is dehydroge-
nated by the dehydrosqualene desaturase CrtN to form the yellow intermediate 4,4=-diaponeurosporene.
Third, oxidation of the terminal methyl group of 4,4=-diaponeurosporene is catalyzed by a mixed-
function oxidase, CrtP, to form 4,4=-diaponeurosporenic acid. Then, glycosyl 4,4=-diaponeurosporenoate
is formed by esteriﬁcation of glucose at the C-1 position of 4,4=-diaponeurosporenic acid via CrtQ, a
glycosyltransferase. Finally, glucose at the C-6 position is esteriﬁed with the carboxyl group of 12-
methyltetradecanoic acid by the acyltransferase CrtO to yield staphyloxanthin (2).
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Inhibition of CrtN by NP16. To exclude the possibility that NP16 is a CrtM inhibitor,
we puriﬁed CrtM protein (see Fig. S1 in the supplemental material) and tested the
activity of CrtM to condense two farnesyl pyrophosphate (FPP) molecules. Consistent
with published data (9), the CrtM inhibitor BPH652 showed nearly 100% inhibition at
10 M, while compound NP16 showed no inhibition, even at 100 M (Fig. 3A).
Overexpression of N-terminal His-tagged CrtN with pQE30N (5) in Escherichia coli
produced no soluble recombinant proteins. We constructed plasmid pET28b-crtN
(Fig. S2A) and transformed it into the BL21(DE3) and Rosetta(DE3) strains, which
showed that although CrtN production was induced with isopropyl--D-thiogalacto-
pyranoside (IPTG), no soluble CrtN was detected (Fig. S2C).
Thus, a His-maltose binding protein (MBP) tag was introduced to increase the
solubility of CrtN along with plasmid pRhisMBP-crtN (Fig. S2B). After treatment with
tobacco etch virus (TEV) protease and removal of the MBP tag, CrtN was puriﬁed and
showed a molecular mass of approximately 55 kDa (Fig. S2D).
The substrate 4,4=-diapophytoene was extracted from the carotenoid fraction from
strain COL-ΔcrtN (Fig. S3). To test CrtN activity, 4,4=-diapophytoene-containing phos-
phatidylcholine liposomes were made and supplemented with 15 g of puriﬁed
protein. This reaction was not active unless supplemented with FAD, as conﬁrmed by
FIG 2 In vitro pigment inhibition by compound NP16. (A) Inhibition of wild-type (WT) S. aureus pigmentation in the presence of
increasing concentrations of NP16. (B) Pigment inhibition by NP16; the IC50 for pigment formation is 300 nM. (C) The chemical
structure of compound NP16. (D) Growth curve of S. aureus COL in the presence of different concentrations of NP16. All data
represent mean values  SD.
FIG 3 Effects of compound NP16 on CrtM and CrtN enzyme activity. (A) The inhibition of CrtM with NP16
and inhibitor BPH-652; the reaction mixture or the reaction mixture without enzyme showed activity
ratios of 1 and 0, respectively. (B) An assay of CrtN enzyme activity was conducted with different
concentrations of NP16, which were monitored by LC-MS. All data represent mean values  SD.
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liquid chromatography-mass spectrometry (LC-MS) analysis of the peak area of sub-
strate.
For inhibition analysis, different concentrations of NP16 were added to the assay
mixture to determine the IC50, and the reaction was monitored via absorbance at
286 nm. The calculated IC50 was 1.341  0.21 M (mean  standard deviation [SD])
(Fig. 3B).
NP16 treatment leads to the accumulation of 4,4=-diapophytoene. To examine
the effect of NP16 on carotenoid production in S. aureus, the extracted carotenoids
were analyzed by LC-MS. The colored components with retention times of around
17.2 min (monitored at 450 nm) were decreased in the NP16 treatment group (Fig. 4A).
Compared with the untreated COL strain, compound NP16 addition revealed a peak at
18.76 min, with a molecular weight of 409.3536 (Fig. 4A; Fig. S3B), which was charac-
terized as 4,4=-diapophytoene by LC-tandem MS (LC-MS/MS).
Mutation and complementation. As CrtM was previously shown to block the
biosynthesis of carotenoids (4), another essential gene, crtN, which encodes dehydros-
qualene desaturase, was investigated. To probe the biological activities of CrtN, we
generated an isogenic crtN mutant in the COL strain via allelic replacement (Fig. S4A
and B). The mutation resulted in loss of yellow pigment.
To complement this mutant strain, pOS1hrtAB-crtN, with a hemin-inducible pro-
moter, was constructed (Fig. S4C). The complementation restored the pigment pro-
duction of COL-ΔcrtN to the wild-type COL level (Fig. 4B).
In comparison with the wild-type COL strain, COL-ΔcrtN showed increased produc-
tion of 4,4=-diapophytoene (Fig. 4A), without any production of pigmented carotenoids
(Fig. 4A). Also, LC-MS analysis showed that the COL-ΔcrtN strain had a comparable
amount of 4,4=-diapophytoene as the NP16-treated wild-type COL strain, which also
indicated that CrtN is the target of NP16.
Without NP16 treatment, hemin induced pigment production in the COL-pOS1hrtAB-crtN
strain. However, in the parent strain carrying pOS1hrtAB, hemin failed to induce
pigment production, conﬁrming that induced pigment production is a result of the
increased expression of crtN in the wild-type COL strain.
Compared with the dimethyl sulfoxide (DMSO) vehicle control group, compound
NP16 treatment at 5 M signiﬁcantly reduced pigment production in the absence of
hemin, whereas with the addition of increasing concentrations of hemin, inhibition
faded away when CrtN was overproduced. In the event that high levels of CrtN are
involved in other pathways, CrtM’s inhibitor, BPH652, was also included in the assay
mixture, and dramatic inhibition was shown, irrespective of the hemin concentration
(Fig. 5A; Fig. S5).
FIG 4 4,4=-Diapophytoene accumulation after NP16 treatment. (A) Comparison of carotenoid compo-
nents among strain COL, COL-ΔcrtN, COL-ΔcrtN-pOS1hrtAB-crtN, or COL-ΔcrtN-pOS1hrtAB-crtN plus
10 M hemin (inducer), or COL treated with NP16. Plasmid pOShrtAB-crtN has a hemin-inducible
promoter. (B) Comparison of the pigmentation of the wild-type COL strain, crtN deletion strain, and crtN
complemented strain.
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As the production of pigment monitored by absorbance may not directly reﬂect the
activity of CrtN in bacterial cells, LC-MS was employed to analyze the substrate of CrtN
and the product of CrtP, to investigate enzyme activity and inhibition.
Deletion of crtN led to the accumulation of 4,4=-diapophytoene, whereas the
complementary expression of CrtN in the mutant strain, without the addition of hemin,
reduced the level of 4,4=-diapophytoene back to that of the parent strain (Fig. 4A).
When crtN expression was increased by adding 10 M hemin, 4,4=-diapophytoene was
consumed and 4,4=-diaponeurosporen-4-al, the product of CrtP with a retention time
around 17.2 min, accumulated (Fig. 4A).
Thus, the proportions of 4,4=-diaponeurosporen-4-al and 4,4=-diapophytoene can be
used to indicate active CrtN. Different concentrations of compound NP16 were used to
test such inhibition in the wild-type COL strain and a CrtN high-expression strain. In the
wild-type COL strain, 16 M NP16 completely blocked the biosynthesis of pigment,
while in the CrtN production strain, 80 M NP16 did not block the reaction (Fig. 5B).
Taken together, these results show that compound NP16 reduced pigment produc-
tion through inhibition of CrtN in bacterial cells.
FIG 5 Homologous expression and intracellular inhibition of CrtN by NP16. (A) Homologous expression of crtN in the wild-type COL
strain, treated with NP16, and with BPH652 combined with different concentrations of hemin to conﬁrm the reduced inhibition ratio
when crtN was overexpressed. (B) LC-MS analysis of the effects of different concentrations of NP16 on the crtN-overexpressing strain
and the parent strain. All data represent mean values  SD.
Anti-Virulence Therapy against S. aureus ®
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NP16 has low cytotoxicity and enhances H2O2 and neutrophil killing. Com-
pound NP16 had little cytotoxicity in MDCK, Vero, A549, Huh-7, or 293T cells, with 50%
toxic concentrations higher than 500 M (Fig. 6A). We found a decrease in pigment
production in S. aureus strain COL grown in the presence of NP16 (Fig. 6B). However,
for the COL-ΔcrtN-pcrtN strain, the crtN overexpression strain, the inhibition by NP16
was decreased. In the mutant strain, with or without compound treatment, the UV
spectrum patterns were similar.
Blocking S. aureus pigment formation led to an increase in the susceptibility of the
pathogen to killing by 1.5% hydrogen peroxide exposure (Fig. 6C). Compared with the
normally pigmented strain COL treated with the DMSO control, the COL-ΔcrtN mutant
and wild-type COL treated with 40 M NP16 were killed more effectively by hydrogen
peroxide by a factor of 16. For the nonpigmented strain COL-ΔcrtN, the susceptibility
was similar, irrespective of NP16 treatment (Fig. 6B). When crtN was overexpressed in
COL, the ability of NP16 to increase the susceptibility of S. aureus to H2O2 treatment was
less obvious.
Neutrophils are the immune system’s key defenders against bacterial infections;
their primary function is to ingest and destroy invading pathogens. Bactericidal activity
can be quantiﬁed by measuring the loss in viability of bacteria cocultured with human
neutrophils (10). As a carotenoid-producing strain (Fig. 6B), COL survived signiﬁcantly
better than strain COL-ΔcrtN or NP16-treated COL in human neutrophils (Fig. 6D). When
neutrophils were treated with diphenyleneiodonium (DPI), a general inhibitor of ﬂavo-
proteins including NADPH oxidase, which abrogates the ability of neutrophils to elicit
oxidative killing of bacteria (10), both COL and NP16-treated COL cells showed similar
FIG 6 NP16 treatment leads to increased sensitivity to oxidation and neutrophil killing. (A) Cytotoxic activity of compound NP16 on different cell
lines. (B) UV spectrum of carotenoids extracted from different strains, with or without NP16 treatment. (C) Increased susceptibility of the
NP16-treated S. aureus COL strain to killing by hydrogen peroxide. (D) Increased susceptibility of the NP16-treated S. aureus COL strain to killing
by neutrophils. All data represent mean values  SD. ns, not signiﬁcant; *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. P values were
determined using GraphPad Prism with an unpaired parametric t test and Welch’s correction.
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survival rates (Fig. 6D), indicating a pivotal role of S. aureus carotenoid in protecting the
pathogen from neutrophil-mediated oxidative killing and the speciﬁcity of NP16 in
disarming this crucial protective mechanism of the invading bacterium.
Animal studies. Using a systemic S. aureus infection model, the enzyme CrtM from
S. aureus was identiﬁed to be a target for anti-infective therapy, based on virulence
factor neutralization (3). A similar model was applied to determine if crtN is also
essential for infections in mice. The loss of staphyloxanthin reduced the invasive disease
potential, as mice inoculated with the isogenic S. aureus mutant strain COL-ΔcrtN
showed smaller bacterial populations in the liver (P  0.0018) and spleen (P 
0.000016) than mice inoculated with 4  108 CFU of wild-type S. aureus (by intraperi-
toneal injection), which led to a sustained infection (Fig. 7A and B). Because the COL
strain is a low-virulence strain, no bacteria were detected in the kidneys from days
1 to 3.
FIG 7 In vivo effect of CrtN and its inhibition by NP16. (A and B) Bacteria recovered from the spleens and
livers of mice infected with the wild-type COL or COL-ΔcrtN strains. (C and D) Bacteria recovered from the
spleens and livers of mice infected with the COL strain, with or without compound NP16 treatment. (E)
Bacteria recovered from the kidneys of mice infected with clinical isolate strain AE052 or strain
AE052-ΔcrtN. (F) Bacteria recovered from the kidneys of mice infected with strain AE052, with or without
compound NP16 treatment. All data represent mean values  the standard errors of the means. *, P 
0.05; **, P  0.01; ***, P  0.001. P values were determined using GraphPad Prism with an unpaired
parametric t test and Welch’s correction.
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Another highly virulent clinical isolate, AE052, and its isogenic S. aureus mutant
lacking the CrtN enzyme were also examined in these tests. Compared to the wild-type
strain, the mutant strain in the kidney was cleared by the host after 72 h postinfection
(Fig. 7E).
With the same intraperitoneal challenge used for the experiment shown in Fig. 7A,
B, and E, one group of mice (n  14) was treated with 0.35 mg of NP16 twice per day
(days1, 0, 1, and 2) and a second group (n 12) was treated with the vehicle control.
Upon sacriﬁcing the mice at 72 h, S. aureus COL bacterial counts in the livers (P 
0.0085) and spleens (P  0.0032) of mice treated with compound NP16 were signiﬁ-
cantly lower than those of the control group (Fig. 7C and D). In the case of AE052
infections, bacterial counts in the kidneys of the mice (n  10 for both groups) treated
with NP16 were signiﬁcantly lower than those of the control group (P  0.0465), with
levels in 6 of 10 animals below the detection threshold, compared to undetectable
levels in only 2 of 10 animals in the control group (Fig. 7F). This result indicates a 98%
decrease in surviving bacteria in the treatment groups infected with COL or AE052.
DISCUSSION
CrtM and CrtN are key enzymes in staphyloxanthin biosynthesis (11). The ﬁrst step
of the pathway, dehydrosqualene synthesis, is similar to an early step in human
cholesterol biosynthesis (3). There is 30% sequence identity between the human SQS
and the bacterial CrtM, and they share signiﬁcant structural features. As a cholesterol-
lowering agent and the most potent inhibitor of CrtM, BPH652 preclinical animal
testing and two human clinical trials have been completed (12, 13). It provides a basis
for rational drug design for use against S. aureus and provides proof of principle for the
utility of an anti-infective drug without direct bactericidal properties that renders a
pathogen susceptible to normal host innate immune clearance. The presence of the
homologue of CrtM, human SQS, has discouraged the employment of CrtM as a
druggable target, and a study focused on improving the speciﬁcity of BPH652 against
CrtM was published recently (9). Compared with CrtM, CrtN has no homologous
enzyme in the human cholesterol biosynthesis pathway, making it an attractive drug
target. A recently proposed CrtN inhibitor, naﬁtiﬁne, is a topically administered anti-
fungal compound (14) that has been shown to suppress chemotaxis, chemokinesis,
chemiluminescence, and superoxide anion production of polymorphonuclear leuko-
cytes when the inhibitor is present at high concentrations (15). The effects of naftiﬁne
are not stable in different organs (from no effect to a reduced bacterial load by nearly
4 logs), and results were inconsistent with a crtN mutant (reduced the bacterial load
from 0.2 to 2 logs at most). This indicates that CrtN should not be the primary target
of naftiﬁne (6).
ROS are employed by phagocytic cells to eliminate bacteria. They are generated by
NADP (NADPH) oxidase (16). The bacterial carotenoids expressed by S. aureusmay have
a protective function against these defensive molecules (4, 17). Evidence supports that
a pigment-deﬁcient S. aureus strain is more sensitive to oxidants, hydrogen peroxide,
and singlet oxygen in vitro, compared to a wild-type S. aureus strain (1). Using an
intrabacterial inhibition assay system, we showed that the isogenic crtN mutant, which
exhibited interrupted carotenoid synthesis, was more sensitive to puriﬁed human
neutrophils. This conﬁrmed the importance of CrtN in the intracellular survival of
S. aureus. However, in DPI-treated neutrophils, bacterial killing appeared to be com-
pletely inhibited, illustrating that the strong effect on clearance of nonpigmented
S. aureus should be mainly contributed by ROS in neutrophils. The compound NP16
showed a negligible effect on increasing susceptibility of the crtN mutant S. aureus
strain, and the crtN S. aureus mutant overexpressed hydrogen peroxide in neutrophils,
indicating the speciﬁc inhibition of NP16 on CrtN. A previous study reported that
staphyloxanthin did not contribute to nasal colonization of S. aureus in mice (3). The
likely reason for the latter ﬁnding is that the infection of mucosal surfaces does not
cause inﬂammation, as the role of staphyloxanthin is to resist the host’s oxidant-based
phagocytic defenses.
Gao et al. ®
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We believe that CrtN is a novel target for a virulence factor-based therapy against
S. aureus. CrtN inhibitors without direct bactericidal properties render the pathogen
susceptible to normal host innate immune clearance. Our approach, as well as other
virulence factor-based concepts (3, 18) for highly speciﬁc antistaphylococcal therapy,
also offers theoretical advantages for reducing the selection pressure that favors the
emergence of drug resistance, both in the pathogen and in normal commensal
microﬂora.
MATERIALS AND METHODS
Bacteria, mice, and chemical reagents. Plasmids used in this study are listed in Table S1 and
S. aureus strains and E. coli strains are listed in Table S2. BALB/c mice were purchased from Charles River
Laboratories, Inc. S. aureus was propagated in Terriﬁc broth (TB) or on TB agar (Life Technologies, Inc.).
Unless otherwise indicated, all experiments were performed with bacteria derived from light-protected
S. aureus 36- to 48-h stationary-phase cultures, the point at which pigmentation phenotypes were readily
apparent.
MIC tests. MICs were determined by inoculating 5 104 S. aureus cells in 100 l brain heart infusion
(BHI) medium in 96-well plates with a serial dilution of antibiotics. The MIC was deﬁned as the minimum
concentration resulting in a cell density less than 0.01 optical density (OD) units at 620 nm, which
corresponded to no visible growth, after incubation for 18 h at 37°C.
Cytotoxicity evaluation of NP16 in different cell lines. The cytotoxicity of NP16 in MDCK, A549,
Vero, Huh-7, and 293T cells was evaluated in an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) (Sigma, Hong Kong) assay according to the manufacturer’s instructions. A toxic control (1%
SDS) was included to ensure that the MTT assay was effective. The highest concentration of NP16 that
could be used was 500 M, due to solubility limitations. SigmaPlot (version 11; Systat Software, Inc., San
Jose, CA) was used for graph plotting. Experiments were repeated twice in triplicate.
Real-time PCR. The preparation of total RNA from S. aureus was performed using RNAprotect
reagent (Qiagen, Germany) according to the manufacturer’s instructions. Brieﬂy, total RNA was prepared
by lysostaphin extraction using 5  108 CFU of bacteria at each time point, followed by further
puriﬁcation with an RNeasy kit (Qiagen, Germany) according to the manufacturer’s instructions. The
quality and quantity of total RNA were conﬁrmed by agarose electrophoresis and UV spectrophotometry,
respectively.
Contaminating chromosomal DNA was removed by DNase treatment (Life Technologies, Inc., Hong
Kong). Puriﬁed S. aureus RNA was reverse transcribed into cDNA by using SuperScript III ﬁrst-strand
synthesis supermix (Life Technologies, Hong Kong) and then subjected to real-time PCR analysis using
an ABI 7500 thermocycler (Life Technologies, Inc.) and Fast SYBR Green master mix (Life Technologies,
Inc.). The relative quantiﬁcation of S. aureus transcripts was determined by the ratio of expression of
target transcripts relative to expression of gyrB. The primers (Table S3) used for real-time PCR experi-
ments were RKP1017 and RKP1018 for crtN and RKP1019 and RKP1020 for crtM.
Cloning of crtM and crtN. Full-length crtM was ampliﬁed by PCR from S. aureus genomic DNA using
the primers RKP875 and RKP876. The complete coding sequence of crtM was digested with NcoI and XhoI
and cloned into the expression vector pET28b (Novagen, Madison, WI).
crtN was ampliﬁed by PCR from S. aureus genomic DNA using primers RKP1325 and RKP1326. The
crtN gene was digested with BamHI and XhoI and cloned into the expression vector phisMBP (19).
CrtM expression, puriﬁcation, and inhibition. E. coli Rosetta(DE3) cells were used to overexpress
histidine-tagged CrtM. An overnight culture was diluted 1% into LB medium containing 50 g/ml
kanamycin. Induction was carried out with 1 mM IPTG for 12 h at 20°C, when the cell culture reached an
OD of 0.6 at 600 nm. The cell extract was centrifuged and loaded onto a Ni-nitrilotriacetic acid (NTA)
column, and CrtM was eluted by using a 75-ml linear gradient of 0 to 0.4 M imidazole in 50 mM Tris-HCl
buffer, pH 7.4.
The CrtM activity assay was carried out in reaction buffer (50 mM Tris-HCl, 1 mM MgCl2, 450 M FPP;
pH 7.4). The compounds investigated were preincubated with 2 g of CrtM for 30 min at 20°C.
All reaction mixtures were incubated at 37°C for 40 min, reactions were terminated by the addition
of 10 l of -mercaptoethanol, and the reaction mixtures were then added to 40 l of coloration reagent
prepared with 2.5% ammonium molybdate in 2.5 M H2SO4. Absorbance (the OD at 595 nm) was recorded
to calculate the relative activity of CrtM.
The IC50 values were obtained by ﬁtting the inhibition data to a normal dose-response curve using
SigmaPlot (version 11; Systat Software, Inc., San Jose, CA).
CrtN expression and puriﬁcation. CrtN with a histidine-MBP tag was overexpressed in E. coli
Rosetta(DE3) cells. A 10-ml overnight culture was transferred into 1 liter of LB medium supplemented
with 100 g/ml ampicillin. Induction was carried out with 1 mM IPTG for 12 h at 16°C at an OD of 0.6
at 600 nm. The cell lysate was loaded onto a Ni-NTA column, and CrtN was eluted using a 75-ml linear
gradient of 0 to 0.4 M imidazole in 50 mM sodium-phosphate buffer with 400 mM sodium chloride at
pH 6.6. The collected fractions were analyzed by SDS-PAGE to conﬁrm the peak for MBP-CrtN. The target
peak fractions were concentrated, and the buffer was exchanged to loading buffer without imidazole and
using a PD-10 column (GE Healthcare). The collected solution was treated with TEV protease at 4°C
overnight. The protein sample was applied to a maltose column, and the ﬂowthrough was collected as
native CrtN protein.
Anti-Virulence Therapy against S. aureus ®
September/October 2017 Volume 8 Issue 5 e01224-17 mbio.asm.org 9
 
m
bio.asm
.org
 o
n
 O
ctober 9, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
Isolation of carotenoids. The substrate (4,4=-diapophytoene) and product (4,4=-diaponeurosporene)
were extracted from strains COL-ΔcrtN and COL-ΔcrtOP. Carotenoids were extracted from cell pellets
using 300 ml of methanol per liter of cultured bacterial pellet until all visible pigments were removed.
After centrifugation (4°C, 8,000  g), colored supernatants were pooled and concentrated to 50 ml by
using an EZ-2 Plus centrifugal evaporator (Genevac Inc., Gardiner, NY). A sample was mixed with 100 ml
of ethanol acetate and 200 ml of NaCl (2.5 M). The extract sample in the upper organic phase was
collected, washed with same volume of distilled water, and dried using the EZ-2 Plus evaporator. Dried
samples were ready for silica gel isolation or were stored at 70°C prior to analysis.
Generation of carotenoid-deﬁcient S. aureus mutants crtN and crtOP. Allelic replacement of
the S. aureus crtN gene with an erythromycin resistance gene [erm(C)] cassette was performed using
PCR-based methods, as previously described (20). PCR was used to amplify an 1,000-bp upstream
fragment of crtN by using the primers RKP1067 and RKP1068, along with an 1,000-bp fragment
immediately downstream of crtN by using the primers RKP1069 and RKP1070. The plasmid pCL52.2K-
ErmC was digested with PstI and HindIII and ligated with the upstream PCR product, and then the same
process was repeated for the downstream PCR product, using BamHI and EcoRI. The generated plasmid
was designated pCL52.2K-crtN, and the gene was conﬁrmed by sequencing (Beijing Genomics Institute
[BGI], Hong Kong). This vector was transformed initially into the permissive S. aureus strain RN4220 and
then into S. aureus strains COL and AE052 by electroporation. Transformants were grown at 30°C and
then shifted to the nonpermissive temperature for plasmid replication (42°C). The shift was repeated
three times, and colonies grown on erythromycin-containing plates rather than erythromycin plus
kanamycin plates were identiﬁed as candidate mutants. Allelic replacement of the crtN allele was
conﬁrmed by pigment phenotype and PCRs documenting the targeted insertion of erm(C) and the
absence of crtN in chromosomal DNA isolated from the ﬁnal mutant, ΔcrtN.
For the deletion of crtOP, pKOR1-mediated gene replacement was performed as described previously
(21). Brieﬂy, sequences upstream and downstream of crtOP were ampliﬁed using primers RKP1530/
RKP1531 and RKP1532/RKP1533, respectively. Another PCR using primers RKP1530 and RKP1532 was
conducted to amplify the deletion fragment. This fragment was then cloned into pKOR1. Following
cloning and ccdB selection in E. coli, the constructed plasmid was then introduced into strain COL by
electroporation using a GenePulser Xcell apparatus (Bio-Rad Laboratories, Inc., Hercules, CA). Gene
replacement colonies were selected according to previously published procedures (21). To check for
successful introduction of the mutations, the resulting mutants were checked by PCR using primers
RKP1552 and RKP1553 and for the target sequences via sequencing. Colonies carrying the expected
mutation that survived were designated mutants.
Extraction of 4,4=-diapophytoene and 4,4=-diaponeurosporene. To purify 4,4=-diapophytoene,
carotenoids collected from strain COL-ΔcrtN were dissolved in hexane and separated on a silica gel
column (2.0 by 30 cm) with pure hexane. To purify 4,4=-diaponeurosporene, carotenoids collected from
the COL-ΔcrtOP mutant were dissolved in hexane and separated on a silica gel column (2.0 by 30 cm)
with pure hexane, followed by increasing the concentration of ethyl acetate to 2% in hexane. The
ﬂowthrough was collected every 10 ml.
The fragments were monitored by thin-layer chromatography (TLC) with a 4:1 petroleum ether:
diethyl ether solvent system, and the spots were visualized using 10% phosphomolybdic acid (PMA) in
ethanol.
LC-MS analysis. A 10-l aliquot of the crude extract or the collected fraction was applied to a
YMC-Pack ODS-A column (4.6 by 150 mm, 5.0 m; YMC America, Inc., Allentown, PA) and eluted under
isocratic conditions with a solvent system (isopropanol from 50% in water with 0.1% triﬂuoroacetic acid
for 5 min, then a gradient from 50% to 95% in 25 min, and then kept at 95% for 5 min) at a ﬂow rate
of 1 ml/min using an Agilent 1200 HPLC system equipped with a photodiode array detector. For
structural elucidation, carotenoids were identiﬁed using a combination of high-performance LC (HPLC)
retention times, UV-visible absorption spectra, and mass fragmentation spectra. Mass fragmentation
spectra were monitored using both negative and positive ion modes in a mass range of m/z 200 to 1,000
on the Varian 1200L LC-MS system equipped with an atmospheric pressure chemical ionization interface.
Preparation of 4,4=-diapophytoene liposomes and CrtN reaction mixtures. Ten milligrams
of phosphatidylcholine (Sigma-Aldrich) was dissolved in 1 ml of CHCl3. Then, 100 nmol of 4,4=-
diapophytoene was added to the mixture. The lipid-phytoene mixture was dried, dissolved with 2 ml of
buffer I (50 mM Tris-HCl [pH 8.0], 100 mM NaCl) on ice for 30 min, and then sonicated on ice for 5 min.
For the enzyme activity assay, 10 g of puriﬁed CrtN was incubated with 100 l of 4,4=-
diapophytoene liposomes (containing 5 nmol of 4,4=-diapophytoene), 150 M ﬂavenine adenine dinu-
cleotide, and buffer II (20 mM phosphate buffer [pH 8.0], 100 mM NaCl) in a total volume of 660 l at
37°C for 2 h (standard assay). The reaction was stopped by adding 1 vol of CHCl3:methaol (MeOH; 2:1
[vol/vol]). Following mixing, the sample was centrifuged at 16,000 g for 10 min. The organic phase was
dried for LC-MS analysis.
Complementation. Primers RKP1333 and RKP1191 were used to amplify the crtN gene from the
chromosome of the wild-type S. aureus COL strain. The fragment was cloned into the vector pOS1hrtAB
(22), and the recombinant plasmid (pOS1hrtAB-crtN) was transformed via electroporation into the
S. aureus COL-ΔcrtN mutant. It included a hemin-inducible promoter hrtAB, and 10 M hemin was
sufﬁcient for inducing expression of the target gene.
Homologous expression and ex vivo enzyme inhibition assay. The wild-type COL strain and the
COL strain transformed with pOS1hrtAB-crtN were cultured with different concentrations of hemin,
ranging from 0 to 10 M. Compounds NP16 and BPH652 were added to different cultures at a
concentration of 10 M. Five-milliliter cultures in 50-ml Falcon tubes were incubated at 37°C, with
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shaking at 250 rpm, for 24 h. Bacteria were collected for the extraction of carotenoids. The extracted
carotenoids were analyzed with a plate reader at an OD of 450. The inhibition ratio of compound NP16
was compared with a DMSO control and BPH652. The wild-type COL strain with hemin added was used
as a control.
The wild-type COL and COL-ΔcrtN-pOS1hrtAB-crtN strains were also cultured in TB medium with
appropriate antibiotics. Hemin was added to 10 M to induce crtN expression in the complemented
strain, and different concentrations of compound NP16, ranging from 80 M to 0.64 M, were added to
monitor the IC50 of the carotenoids. Sample collection was similar to that of the homologous expression
assay. After the extraction of carotenoids, LC-MS was used to analyze the inhibition by compound NP16
and to monitor ex vivo enzyme inhibition. The peak areas of the target component were integrated and
calculated to obtain the differences in IC50s.
Hydrogen peroxide susceptibility assay. S. aureus was grown in BHI with or without NP16 (40 M).
After 2 days, bacteria were washed twice in phosphate-buffered saline (PBS) and diluted to a concen-
tration of 1  107 CFU per 100-l reaction mixture in a 96-well plate. H2O2 in PBS was added to a 440
mM ﬁnal concentration, and the plate was incubated for 1 h at 37°C with shaking. The reaction was
stopped by the addition of 1,000 U/ml of exogenous catalase (Sigma-Aldrich, St. Louis, MO), and bacterial
viability was assessed by plating dilutions on BHI agar plates.
Isolation of human neutrophils. The isolation of human neutrophils was conducted by the gradient
density centrifugation method as reported by Freitas et al. (23), with Histopaque solutions 1077 and 1119
in 12-ml polypropylene centrifuge tubes. Brieﬂy, 3 ml of Histopaque 1077 was carefully layered on top
of 3 ml of Histopaque 1119 in a 12-ml polypropylene tube. Then, 6 ml of collected blood was layered on
top. After centrifugation at 890  g for 30 min at 20°C, the neutrophils were carefully collected using a
Pasteur pipette. The neutrophils doubled in volume when we used PBS lacking Ca2	 and Mg2	. After
centrifugation at 870  g for 5 min at 4°C, the pellet was resuspended with a mixture of 1.25 ml of PBS
(lacking Ca2	 and Mg2	) and 5.25 ml of sterile distilled water to lyse any remaining red blood cells. The
tube was gently inverted for 1.30 min, and 2.2 ml of 3% NaCl was added. After another centrifugation
at 870  g for 5 min at 4°C, the neutrophil pellet was resuspended in PBS containing Ca2	 and Mg2	.
Isolated neutrophils were kept on ice until use. Neutrophils from one volunteer were used per
experiment.
Bactericidal activity of polymorphonuclear leukocytes. The killing of S. aureus by human poly-
morphonuclear leukocytes (PMNs) was determined as previously described (24), with some modiﬁca-
tions. Brieﬂy, PMNs (107) treated or not with 10 M DPI were mixed with 108 opsonized S. aureus
bacteria (multiplicity of infection, 10) in 24-well tissue culture plates. After centrifugation at 380  g for
8 min, plates were incubated at 37°C for up to 1.5 h. PMNs were lysed with saponin (20 min on ice) and
plated on BHI agar plates. The percent survival was calculated by normalization with time zero results.
Statistics were performed with Student’s t test (GraphPad Prism).
Murine model of intraperitoneal infection. Eight- to 10-week-old female BALB/c mice were
injected intraperitoneally (i.p.) with 4  108 CFU of early-stationary-phase S. aureus COL cells. After
3 days, animals were euthanized, the livers and spleens were isolated, then homogenized in PBS, and
plated to obtain viable counts. For the treatment study, mice were randomized into two groups at the
start of the experiment and administered i.p. either 0.35 mg of NP16 or PBS with 5% Tween 80 as a
control, twice per day, starting on day1 to day 2 (a total of eight doses for each animal). Intraperitoneal
challenge with 4  108 CFU of early-stationary-phase S. aureus COL cells was performed on day 0. The
mice were sacriﬁced on day 3 for enumeration of bacterial CFU in liver and spleen homogenates. Ten
mice were used in the ﬁrst experiment, and 13 were used in the second. All results were pooled for
statistical analysis.
For the clinical isolate S. aureus strain AE052, all operations were similar to those used for the COL
strain, except 108 CFU of early-stationary-phase bacteria were used in the infection model, and kidneys
were collected for monitoring bacterial loads. Statistics were performed using Student’s t test (GraphPad
Prism).
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